AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Blood Cancer Talks
The Top Line Results for Progression Free Survival With Silticell
Dr. Cohen, can you tell us a top line results for progression free survival with calm three as well as category four? Yes. For Karma 3, which was the more heavily pre-treated population, the key results that the Ida cell did meet the primary endpoint of improving progression for survival. B&PFS was 13.3 months versus 4.4 months for the standard of care arm. And so, similar to the later line studies, we saw that Silticell performed much better than Ida cell in terms of CR rate and median BFS.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode